US 11,970,457 B2
Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine
William Kenneth Banner, Greensboro, NC (US); Bapu Gaddam, Ellicott City, MD (US); Dharma Rao Polisetti, High Point, NC (US); Robert Carl Andrews, Jamestown, NC (US); and Samuel Victory, Winston-Salem, NC (US)
Assigned to VTV THERAPEUTICS LLC, High Point, NC (US)
Filed by vTv Therapeutics LLC, High Point, NC (US)
Filed on Oct. 27, 2022, as Appl. No. 18/050,211.
Application 18/050,211 is a continuation of application No. 17/211,942, filed on Mar. 25, 2021, granted, now 11,524,942.
Application 17/211,942 is a continuation of application No. PCT/US2019/054928, filed on Oct. 7, 2019.
Claims priority of provisional application 62/828,026, filed on Apr. 2, 2019.
Claims priority of provisional application 62/743,757, filed on Oct. 10, 2018.
Prior Publication US 2023/0183183 A1, Jun. 15, 2023
Int. Cl. C07D 233/64 (2006.01)
CPC C07D 233/64 (2013.01) 12 Claims
 
1. A pharmaceutical composition comprising:
between 0.1 mg and 100 mg of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine or a pharmaceutically acceptable salt thereof;
between 0.0001% to 5% by weight of 4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenol or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.